Sign in

    Emily Christy • Piper Sandler

    Emily Christy is an analyst at Piper Sandler specializing in commercial analytics, with a focus on providing data-driven insights for the healthcare and life sciences sectors. While her exact company coverage and performance track record are not publicly detailed, her role centers on supporting investment decisions in these industries. Prior to joining Piper Sandler, there is no verified information on her previous employment or specific career timeline. Her publicly available credentials do not list specific FINRA registrations or securities licenses, and no notable rankings or industry recognitions have been identified at this time.

    Emily Christy's questions to Clearpoint Neuro Inc (CLPT) leadership

    Emily Christy's questions to Clearpoint Neuro Inc (CLPT) leadership • Q3 2024

    Question

    Emily Christy of Piper Sandler inquired about the key tailwinds and headwinds for ClearPoint Neuro heading into 2025, any potential inflection points like GLP readiness, and whether the recent accelerated pace of new system placements is the new sustainable norm.

    Answer

    Joseph Burnett, CEO, responded that he sees significant tailwinds and no major headwinds. He highlighted growth drivers including Medtronic's new FDA labeling for 'sleep DBS' procedures, which could increase patient adoption by addressing fears of being awake during surgery. He also pointed to growing demand for laser therapy and the revenue potential from partners' advancing clinical trials. Burnett confirmed that the recent headwind from the Russell 2000 index rebalancing should become a tailwind in 2025. Regarding system placements, he stated that a double-digit annual placement rate is the 'new normal,' a significant increase from the historical 6-8 per year.

    Ask Fintool Equity Research AI